# Empagliflozin (Jardiance)

Source: https://ourhealthnetwork.com/drugs/empagliflozin
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Empagliflozin?

Empagliflozin (brand name: Jardiance) is a sglt2 inhibitor. It is prescribed to treat diabetes mellitus, type 2. Across the United States, 160,000 doctors prescribe Empagliflozin to approximately 1.4 million Medicare patients, making it one of the 50 most prescribed drugs in America.

## Brand names

Jardiance

## Indications

Empagliflozin is prescribed for the treatment of diabetes mellitus and type 2.

## Conditions treated

- [Diabetes Mellitus](https://ourhealthnetwork.com/conditions/diabetes-mellitus)
- [Type 2](https://ourhealthnetwork.com/conditions/type-2)

## Mechanism of action

SYNJARDY or SYNJARDY XR SYNJARDY and SYNJARDY XR contain: empagliflozin, a SGLT2 inhibitor, and metformin HCl, a biguanide. Empagliflozin Empagliflozin is an inhibitor of SGLT2, the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation.

## Drug classification

- Established Pharmacologic Class: SGLT2 Inhibitor
- Mechanism of Action class: Sodium-Glucose Transporter 2 Inhibitors [MoA]
- Route of administration: ORAL

## Common side effects

urinary tract infection, upper respiratory infection, increased urination, joint pain

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)